OBJECTIVE: To assess the efficacy and safety of avocado/ @entity1460 unsaponifiables (ASU) in the treatment of @entity1 with symptomatic @entity571 ( @entity571 ) of the knee or hip, as well as the potential residual effects of ASU after stopping treatment, to determine whether ASU might be a symptomatic slow-acting drug for the treatment of @entity571 . METHODS: One hundred sixty-four @entity1 with regular, painful, primary @entity571 of the knee (n = 114) or hip (n = 50) entered a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial with a 6-month treatment period and a 2-month posttreatment followup. A 15-day washout period for nonsteroidal antiinflammatory drugs (NSAIDs) preceded the study. Efficacy was judged according to 1) Lequesne's functional index (LFI) and 2) @entity158 on Huskisson's visual analog scale (VAS; 100-mm scale), intake of NSAIDs/analgesics, and overall disability score (by 100-mm VAS). RESULTS: Eighty-five @entity1 received ASU; 79 received placebo. One hundred forty-four @entity1 were evaluable at month 6 (75 taking ASU; 69 taking placebo). The mean +/- SEM LFI score decreased from 9.7 +/- 0.3 to 6.8 +/- 0.4 in the ASU group and from 9.4 +/- 0.3 to 8.9 +/- 0.4 in the placebo group (P < 0.001 for intergroup difference at month 6). @entity158 decreased from 56.1 +/- 1.6 mm to 35.3 +/- 2.3 in the ASU group and from 56.1 +/- 1.8 mm to 45.7 +/- 2.6 in the placebo group (P = 0.003 at month 6). NSAID consumption was slightly lower in the ASU group. Fewer @entity1 in the ASU group required NSAIDs (48%, versus 63% in the placebo group; P = 0.054). The success rate was 39% in the ASU group and 18% in the placebo group. Overall functional disability was significantly reduced in the ASU group. Improvement appeared more marked in @entity1 with @entity570 . A residual effect was observed at month 8. Tolerance was good to excellent for most @entity1 . CONCLUSION: ASU treatment showed significant symptomatic efficacy over placebo in the treatment of @entity571 , acting from month 2 and showing a persistent effect after the end of treatment.

Symptomatic efficacy of avocado/ @entity1460 unsaponifiables in the treatment of XXXX of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis', 'OA'] @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain'] @entity1460 :: ('3847', 'Species') :: ['soybean'] @entity570 :: ('MESH:D015207', 'Disease') :: ['hip OA']
@entity571 :: (MESH:D010003,Disease) :: ['osteoarthritis']
